1. ALLA AKTIER
  2. NYHETER
  3. BIO-WORKS TECHNOLOGIES

Bio-Works Technologies

Nyheter Bio-Works Technologies Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Bio-Works receives second order worth 2.4 MSEK order from customer in Netherlands

MAR

Bio-Works has received a second order from the same production customer in Netherlands who ordered last week. The second order is worth 2.4 MSEK. The order is a scale-up order for a project to which Bio-Works has previously delivered at R&D scale. The customer is a global manufacturer of active pharmaceutical ingredients (APIs) with approximately 1,800 employees.

“We are very happy to have received this second order from a customer who has previously had good experience with WorkBeads Q resin for anion exchange chromatography and is now scaling-up a second production step using our WorkBeads S resin for cation exchange chromatography. Our existing customers rate our products and service very highly, and this is yet another example of a production customer expanding their business with us,” said Jonathan Royce, CEO at Bio-Works.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB is appointed Certified Adviser. For more information, visit www.bio-works.com.

This information is information that Bio-Works Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-01-23 15:55 CET.

Attachments
Bio-Works receives second order worth 2.4 MSEK order from customer in Netherlands

Datum 2024-01-23, kl 15:55
Källa MFN
Bifogade filer
Bio-Works receives second order worth 2.4 MSEK order from customer in Netherlands